Gustavo J. Pesquin is the CEO of Amneal Pharmaceuticals, where he focuses on commercial operations. He has a solid track record in the pharmaceutical industry, previously working for Sanofi for 11 years, where he led their North America General Medicines...

Gustavo J. Pesquin is the CEO of Amneal Pharmaceuticals, where he focuses on commercial operations. He has a solid track record in the pharmaceutical industry, previously working for Sanofi for 11 years, where he led their North America General Medicines division. Gustavo has a strong academic background with an M.B.A. from Northwestern University's Kellogg School and a degree from Universidad Nacional de Cuyo in Argentina. His hiring as Executive Vice President and Chief Commercial Officer in September 2022 marked a strategic move for Amneal, pointing towards growth in specialty pharmaceuticals. Gustavo's leadership style emphasizes results, as reflected in the bonus structure tied to company performance metrics like revenue growth and EBITDA. Under his guidance, Amneal aims to innovate and expand in the competitive pharma landscape. He holds significant stock in the company, highlighting his belief in Amneal's potential and aligning his interests with shareholders. With a wealth of experience across various influential roles in well-known companies, he continues to lead Amneal with a focus on delivering value to both customers and investors.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Amneal Pharmaceuticals, Inc. CEOs

A

Gustavo J. Pesquin

CEO of Amneal Pharmaceuticals, Inc.

Education

M.B.A. from Kellogg GSM, Northwestern University and a B.A. from Universidad Nacional de Cuyo in Argentina.

Sector of Economy

Healthcare

Born

January 1, 1970 - 55 years ago

CEO of Amneal Pharmaceuticals, Inc. for

2 years 9 months (Sep 2022 - Present)

Previous Experience

North America Head for General Medicines at Sanofi US.

Rivals

Competitors/colleagues of Gustavo J. Pesquin

Holdings

See how much did Gustavo J. Pesquin make over time.

Gustavo J. Pesquin's holdings in Amneal Pharmaceuticals demonstrate his confidence in the company. As of 2023, he possesses stocks valued at around $300,000 derived from 20,000 restricted stock units (RSUs) that vested this year. In the previous year, he had...

Gustavo J. Pesquin's holdings in Amneal Pharmaceuticals demonstrate his confidence in the company. As of 2023, he possesses stocks valued at around $300,000 derived from 20,000 restricted stock units (RSUs) that vested this year. In the previous year, he had also vested 10,000 RSUs worth around $150,000. This indicates a steady accumulation of shares over his tenure. His significant stake reflects a long-term commitment to the company's success, especially considering his holdings reached their peak value as he took on leadership roles within Amneal. The growth in the value of his vested stocks illustrates a confident trajectory for both his wealth and the company's performance.

Loading...

Insider Trading

See recent insider trades of Gustavo J. Pesquin.

No insider trades found for this CEO.

Compensation History

See how much did Gustavo J. Pesquin make over time.

In 2023, Gustavo J. Pesquin's total compensation as CEO of Amneal Pharmaceuticals reached $950,000. This included a base salary of $500,000, a performance-based bonus of $100,000, and $300,000 from vested stock units. His bonus is tied to key performance indicators such as revenue growth and EBITDA, ensuring that his incentives align with the company's success. In 2022, he earned a total of $680,000, with a similar structure to his compensation in 2023, reinforcing a consistent approach to retaining top talent and encouraging performance at Amneal. The architecture of his compensation reflects both the company's objectives and his potential to influence its direction.

Year

2023

Total Compensation

$950.00K

Salary

$500.00K

Board Justification

The compensation philosophy aligns with company performance and aims to retain top talent through competitive pay structures.

Bonus

$100.00K

Board Justification

The bonus is based on the company's performance metrics including revenue growth and EBITDA targets for the fiscal year 2023.

Other

$50.00K

Board Justification

Other compensation includes health benefits and retirement contributions.

Restricted Stock

$300.00K(20K RSU)

Board Justification

The vested stock consists of RSUs that were granted in previous years and vested in 2023.

Performance Metrics

Performance metrics include revenue growth, EBITDA targets, and overall company performance relative to peers.

Other Amneal Pharmaceuticals, Inc. CEOs

Here are other CEOs of Amneal Pharmaceuticals, Inc.

Chintu Patel

Founder and Ex-CEO of Amneal Pharmaceuticals, Inc.

August 2019 - March 2022